Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Constanze Heinzel"'
Autor:
Freisnel H. Mouzinga, Constanze Heinzel, Abel Lissom, Andrea Kreidenweiss, Armel L. Batchi‐Bouyou, Jacques D. Mbama Ntabi, Jean C. Djontu, Etienne Ngumbi, Peter G. Kremsner, Rolf Fendel, Francine Ntoumi
Publikováno v:
Immunity, Inflammation and Disease, Vol 11, Iss 12, Pp n/a-n/a (2023)
Abstract Background The efficacy of immunization against an airborne pathogen depends in part on its ability to induce antibodies at the major entry site of the virus, the mucosa. Recent studies have revealed that mucosal immunity is poorly activated
Externí odkaz:
https://doaj.org/article/75c2ceb95ac147daa5942a83bbbd756f
Autor:
Thaisa Lucas Sandri, Juliana Inoue, Johanna Geiger, Johanna-Marie Griesbaum, Constanze Heinzel, Michael Burnet, Rolf Fendel, Peter G. Kremsner, Jana Held, Andrea Kreidenweiss
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract The pandemic caused by SARS-CoV-2 resulted in increasing demands for diagnostic tests, leading to a shortage of recommended testing materials and reagents. This study reports on the performance of self-sampled alternative swabbing material (
Externí odkaz:
https://doaj.org/article/e4a03982c6a84819bad572abfc336e46
Autor:
Matthias Becker, Alex Dulovic, Daniel Junker, Natalia Ruetalo, Philipp D. Kaiser, Yudi T. Pinilla, Constanze Heinzel, Julia Haering, Bjoern Traenkle, Teresa R. Wagner, Mirjam Layer, Martin Mehrlaender, Valbona Mirakaj, Jana Held, Hannes Planatscher, Katja Schenke-Layland, Gérard Krause, Monika Strengert, Tamam Bakchoul, Karina Althaus, Rolf Fendel, Andrea Kreidenweiss, Michael Koeppen, Ulrich Rothbauer, Michael Schindler, Nicole Schneiderhan-Marra
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-8 (2021)
Here, the authors characterize the antibody response from vaccinated (Pfizer BNT-162b2), infected and uninfected individuals against emerging variants of concern of SARS-CoV-2, finding reduced neutralization of a South African isolate. High IgG titer
Externí odkaz:
https://doaj.org/article/b1f0cfb4a3c942a594406b501e462f7e
Autor:
Yudi T. Pinilla, Constanze Heinzel, Lena-Fabienne Caminada, Douglas Consolaro, Meral Esen, Peter G. Kremsner, Jana Held, Andrea Kreidenweiss, Rolf Fendel
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
SARS-CoV-2 antibodies in saliva serve as first line of defense against the virus. They are present in the mucosa, more precisely in saliva, after a recovered infection and also following vaccination. We report here the antibody persistence in plasma
Externí odkaz:
https://doaj.org/article/7dec9b1bdec34130bb2abe8817aa6c4f
Autor:
Yudi T Pinilla, Evelyn Friessinger, Johanna Marie Griesbaum, Lilith Berner, Constanze Heinzel, Käthe Elsner, Rolf Fendel, Jana Held, Andrea Kreidenweiss
Publikováno v:
JMIR Research Protocols, Vol 10, Iss 10, p e27739 (2021)
BackgroundThe world has been confronted with the COVID-19 pandemic for more than one year. Severe disease is more often found among elderly people, whereas most young children and adolescents show mild symptoms or even remain asymptomatic, so that in
Externí odkaz:
https://doaj.org/article/bac2ac62f1d34307a3d8e2722b88ddff
Autor:
Constanze Heinzel, Yudi T. Pinilla, Käthe Elsner, Evelyn Friessinger, Benjamin Mordmüller, Peter G. Kremsner, Jana Held, Rolf Fendel, Andrea Kreidenweiss
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Saliva is a body fluid with hitherto unused potential for the assessment of SARS-CoV-2 antibodies. Specific antibodies can indicate a past SARS-CoV-2 infection and allow to estimate the proportion of individuals with a potential protective immunity.
Externí odkaz:
https://doaj.org/article/85e579c8c7684d8797813a6f2fd4fa4f
Autor:
Constanze Heinzel, Yudi T. Pinilla, Ayla Binder, Peter G. Kremsner, Jana Held, Rolf Fendel, Andrea Kreidenweiss
Publikováno v:
JAMA Pediatrics.
This cross-sectional study evaluates IgG antibody levels in children and adolescents in Germany following SARS-CoV-2 infection.
Autor:
Merel J Smit, Adam F Sander, Maud B P A Ariaans, Cyrielle Fougeroux, Constanze Heinzel, Rolf Fendel, Meral Esen, Peter G Kremsner, Rob ter Heine, Heiman F Wertheim, Manja Idorn, Søren Riis Paludan, Alexander P Underwood, Alekxander Binderup, Santseharay Ramirez, Jens Bukh, Max Soegaard, Sayit M Erdogan, Tobias Gustavsson, Stine Clemmensen, Thor G Theander, Ali Salanti, Mette Hamborg, Willem A de Jongh, Matthew B B McCall, Morten A Nielsen, Benjamin G Mordmüller, Robert Dagil, Louise Goksøyr, Thomas M Hulen, Christoph Janitzek, Daniel S Jensen, Sune Justesen, Paul K Khalifé, Andrea Kreidenweiss, Telma Lança, Olivia Lie-Andersen, Karina Teelen, Elena Vidal-Calvo
Publikováno v:
Smit, M J & COUGH-1 trial study group 2023, ' First-in-human use of a modular capsid virus-like vaccine platform : An open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2 ', The Lancet Microbe, vol. 4, no. 3, pp. e140-e148 . https://doi.org/10.1016/S2666-5247(22)00337-8
The Lancet Microbe, 4, 3, pp. e140-e148
The Lancet Microbe, 4, e140-e148
The Lancet Microbe, 4, 3, pp. e140-e148
The Lancet Microbe, 4, e140-e148
Contains fulltext : 291067.pdf (Publisher’s version ) (Open Access) BACKGROUND: Capsid virus-like particles (cVLP) have proven safe and immunogenic and can be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP COV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e14ac00b940c34782ba1e1c8bde5833a
https://curis.ku.dk/ws/files/340399546/1_s2.0_S2666524722003378_main.pdf
https://curis.ku.dk/ws/files/340399546/1_s2.0_S2666524722003378_main.pdf
Autor:
Daniel, Junker, Matthias, Becker, Teresa R, Wagner, Philipp D, Kaiser, Sandra, Maier, Tanja M, Grimm, Johanna, Griesbaum, Patrick, Marsall, Jens, Gruber, Bjoern, Traenkle, Constanze, Heinzel, Yudi T, Pinilla, Jana, Held, Rolf, Fendel, Andrea, Kreidenweiss, Annika, Nelde, Yacine, Maringer, Sarah, Schroeder, Juliane S, Walz, Karina, Althaus, Gunalp, Uzun, Marco, Mikus, Tamam, Bakchoul, Katja, Schenke-Layland, Stefanie, Bunk, Helene, Haeberle, Siri, Göpel, Michael, Bitzer, Hanna, Renk, Jonathan, Remppis, Corinna, Engel, Axel R, Franz, Manuela, Harries, Barbora, Kessel, Berit, Lange, Monika, Strengert, Gerard, Krause, Anne, Zeck, Ulrich, Rothbauer, Alex, Dulovic, Nicole, Schneiderhan-Marra
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
The rapid emergence of the omicron variant and its large number of mutations led to its classification as a variant of concern (VOC) by the WHO. Subsequently, omicron evolved into distinct sublineages (e.g. BA1 and BA2), which currently represent the
Autor:
Daniel Junker, Matthias Becker, Teresa R. Wagner, Philipp D. Kaiser, Sandra Maier, Tanja M. Grimm, Johanna Griesbaum, Patrick Marsall, Jens Gruber, Bjoern Traenkle, Constanze Heinzel, Yudi T. Pinilla, Jana Held, Rolf Fendel, Andrea Kreidenweiss, Annika Nelde, Yacine Maringer, Sarah Schroeder, Juliane S. Walz, Karina Althaus, Gunalp Uzun, Marco Mikus, Tamam Bakchoul, Katja Schenke-Layland, Stefanie Bunk, Helene Haeberle, Siri Göpel, Michael Bitzer, Hanna Renk, Jonathan Remppis, Corinna Engel, Axel R. Franz, Manuela Harries, Barbora Kessel, Monika Strengert, Gerard Krause, Anne Zeck, Ulrich Rothbauer, Alex Dulovic, Nicole Schneiderhan-Marra
The rapid emergence of the Omicron variant and its large number of mutations has led to its classification as a variant of concern (VOC) by the WHO(1). Initial studies on the neutralizing response towards this variant within convalescent and vaccinat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a78496458daf8d61dd95f92e345463d4
https://doi.org/10.1101/2021.12.30.21267519
https://doi.org/10.1101/2021.12.30.21267519